{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:43:52Z","timestamp":1792025032020,"version":"4.4.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/igo\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["222044\/Z\/20\/Z"],"award-info":[{"award-number":["222044\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.vaccine.2025.127515","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T09:21:07Z","timestamp":1752916867000},"page":"127515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Non-typhoidal Salmonella combination vaccines: clinical development plan and regulatory considerations"],"prefix":"10.1016","volume":"62","author":[{"given":"Jean-Louis","family":"Excler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Saluja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Wilder-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calman A.","family":"MacLennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cavaleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127515_bb0005","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jinf.2021.06.029","article-title":"Incidence of non-typhoidal Salmonella invasive disease: a systematic review and meta-analysis","volume":"83","author":"Marchello","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2025.127515_bb0010","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01974-19","article-title":"A systematic review and Meta-analysis of the prevalence of community-onset bloodstream infections among hospitalized patients in Africa and Asia","volume":"64","author":"Marchello","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 4","key":"10.1016\/j.vaccine.2025.127515_bb0015","doi-asserted-by":"crossref","first-page":"S363","DOI":"10.1093\/cid\/civ691","article-title":"Three epidemics of invasive multidrug-resistant Salmonella bloodstream infection in Blantyre, Malawi, 1998-2014","volume":"61","author":"Feasey","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127515_bb0020","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-080501","article-title":"Examining geospatial and temporal distribution of invasive non-typhoidal Salmonella disease occurrence in sub-Saharan Africa: a systematic review and modelling study","volume":"14","author":"Kim","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2025.127515_bb0025","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1016\/S2214-109X(17)30022-0","article-title":"Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study","volume":"5","author":"Marks","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2025.127515_bb0030","first-page":"8","article-title":"Invasive nontyphoidal Salmonella disease in Africa","author":"Gilchrist","year":"2019","journal-title":"EcoSal Plus"},{"key":"10.1016\/j.vaccine.2025.127515_bb0035","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S1473-3099(21)00615-0","article-title":"Complications and mortality of non-typhoidal salmonella invasive disease: a global systematic review and meta-analysis","volume":"22","author":"Marchello","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127515_bb0040","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12916-020-01652-4","article-title":"Invasive non-typhoidal Salmonella infections in sub-Saharan Africa: a systematic review on antimicrobial resistance and treatment","volume":"18","author":"Tack","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2025.127515_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008440","article-title":"High relatedness of invasive multi-drug resistant non-typhoidal Salmonella genotypes among patients and asymptomatic carriers in endemic informal settlements in Kenya","volume":"14","author":"Kariuki","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2025.127515_bb0050","first-page":"6","article-title":"The genomic epidemiology of multi-drug resistant invasive non-typhoidal Salmonella in selected sub-Saharan African countries","author":"Park","year":"2021","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.vaccine.2025.127515_bb0055","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1038\/s41467-023-41152-6","article-title":"A genomic appraisal of invasive Salmonella typhimurium and associated antibiotic resistance in sub-Saharan Africa","volume":"14","author":"Van Puyvelde","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.127515_bb0060","article-title":"Prevalence and distribution of non-typhoidal Salmonella enterica serogroups and serovars isolated from normally sterile sites: a global systematic review","volume":"152","author":"Hagedoorn","year":"2023","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2025.127515_bb0065","doi-asserted-by":"crossref","first-page":"1282894","DOI":"10.3389\/fmicb.2023.1282894","article-title":"Invasive non-typhoidal Salmonella from stool samples of healthy human carriers are genetically similar to blood culture isolates: a report from the Democratic Republic of the Congo","volume":"14","author":"Mbuyi-Kalonji","year":"2023","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2025.127515_bb0070","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/cid\/ciy386","article-title":"Determining the best immunization strategy for protecting African children against invasive Salmonella disease","volume":"67","author":"Jeon","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127515_bb0075","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1016\/S2214-109X(24)00007-X","article-title":"Incidence of typhoid fever in Burkina Faso, Democratic Republic of the Congo, Ethiopia, Ghana, Madagascar, and Nigeria (the severe typhoid in Africa programme): a population-based study","volume":"12","author":"Marks","year":"2024","journal-title":"Lancet Glob Health"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2025.127515_bb0080","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/cid\/civ893","article-title":"The relationship between invasive nontyphoidal Salmonella disease, other bacterial bloodstream infections, and malaria in sub-Saharan Africa","volume":"62","author":"Park","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127515_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003979","article-title":"Modelling the contributions of malaria, HIV, malnutrition and rainfall to the decline in paediatric invasive non-typhoidal Salmonella disease in Malawi","volume":"9","author":"Feasey","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2025.127515_bb0090","doi-asserted-by":"crossref","unstructured":"Rts SCTP, Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, et al. A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants. N Engl J Med 2012;367:2284\u201395.","DOI":"10.1056\/NEJMoa1208394"},{"key":"10.1016\/j.vaccine.2025.127515_bb0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"Rts","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.127515_bb0100","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial","volume":"397","author":"Datoo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.127515_bb0105","doi-asserted-by":"crossref","first-page":"e1059","DOI":"10.1016\/S2214-109X(24)00092-5","article-title":"Facilitating the development of urgently required combination vaccines","volume":"12","author":"Hausdorff","year":"2024","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2025.127515_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105424","article-title":"Identifying WHO global priority endemic pathogens for vaccine research and development (R&D) using multi-criteria decision analysis (MCDA): an objective of the immunization agenda 2030","volume":"110","author":"Hasso-Agopsowicz","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2025.127515_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127008","article-title":"Landscape analysis of invasive non-typhoidal salmonella (iNTS) disease and iNTS vaccine use case and demand: report of a WHO expert consultation","volume":"55","author":"Emary","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127515_bb0120","unstructured":"World Health Organization. Research and development technology roadmap for invasive non-typhoidal Salmonella vaccines against invasive disease. 2025. https:\/\/iris.who.int\/handle\/10665\/381497."},{"key":"10.1016\/j.vaccine.2025.127515_bb0125","unstructured":"World Health Organization. WHO preferred product characteristics for invasive non-typhoidal Salmonella vaccines. 2025. https:\/\/iris.who.int\/handle\/10665\/381542."},{"key":"10.1016\/j.vaccine.2025.127515_bb0130","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1172\/JCI33998","article-title":"The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children","volume":"118","author":"MacLennan","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2025.127515_bb0135","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/infdis\/jiu045","article-title":"Sequential acquisition of T cells and antibodies to nontyphoidal Salmonella in Malawian children","volume":"210","author":"Nyirenda","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127515_bb0140","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.12688\/gatesopenres.13034.1","article-title":"Cross-sectional study of IgG antibody levels to invasive nontyphoidal Salmonella LPS O-antigen with age in Uganda","volume":"3","author":"Stockdale","year":"2019","journal-title":"Gates Open Res"},{"key":"10.1016\/j.vaccine.2025.127515_bb0145","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1073\/pnas.0910497107","article-title":"Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal Salmonella by blood cells in Africans","volume":"107","author":"Gondwe","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2025.127515_bb0150","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00057-17","article-title":"Loss of humoral and cellular immunity to invasive nontyphoidal Salmonella during current or convalescent plasmodium falciparum infection in Malawian children","volume":"24","author":"Nyirenda","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2025.127515_bb0155","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.micinf.2017.11.014","article-title":"Immunological bases of increased susceptibility to invasive nontyphoidal Salmonella infection in children with malaria and anaemia","volume":"20","author":"Nyirenda","year":"2018","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2025.127515_bb0160","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3389\/fimmu.2014.00635","article-title":"Antibodies and protection against invasive salmonella disease","volume":"5","author":"MacLennan","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2025.127515_bb0165","first-page":"9","article-title":"A Salmonella typhi controlled human infection study for assessing correlation between bactericidal antibodies and protection against infection induced by typhoid vaccination","author":"Jones","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2025.127515_bb0170","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1128\/IAI.70.7.3457-3467.2002","article-title":"Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers","volume":"70","author":"Hindle","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.127515_bb0175","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1093\/ofid\/ofad041","article-title":"Salmonella combination vaccines: moving beyond typhoid","volume":"10","author":"MacLennan","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127515_bb0180","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1016\/j.vaccine.2016.03.072","article-title":"Nontyphoidal salmonella disease: current status of vaccine research and development","volume":"34","author":"Tennant","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127515_bb0185","doi-asserted-by":"crossref","first-page":"10428","DOI":"10.1073\/pnas.1807655115","article-title":"Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella","volume":"115","author":"Micoli","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2025.127515_bb0190","first-page":"8","article-title":"GMMA is a versatile platform to design effective multivalent combination vaccines","author":"Micoli","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127515_bb0195","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/14760584.2023.2299384","article-title":"Multiple antigen presenting system (MAPS): state of the art and potential applications","volume":"23","author":"Malley","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127515_bb0200","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.vaccine.2020.11.040","article-title":"Bivalent non-typhoidal Salmonella outer membrane vesicles immunized mice sera confer passive protection against gastroenteritis in a suckling mice model","volume":"39","author":"Maiti","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127515_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2022.152183","article-title":"Development of a novel trivalent invasive non-typhoidal Salmonella outer membrane vesicles based vaccine against salmonellosis and fowl typhoid in chickens","volume":"227","author":"Maiti","year":"2022","journal-title":"Immunobiology"},{"key":"10.1016\/j.vaccine.2025.127515_bb0210","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00430-024-00805-z","article-title":"Trivalent outer membrane vesicles-based combination vaccine candidate induces protective immunity against Campylobacter and invasive non-typhoidal Salmonella in adult mice","volume":"213","author":"Banerjee","year":"2024","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2025.127515_bb0215","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1093\/cid\/ciaa514","article-title":"Overview of the nontyphoidal and paratyphoidal Salmonella vaccine pipeline: current status and future prospects","volume":"71","author":"Baliban","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127515_bb0220","series-title":"More typhoid conjugate vaccines, more impact","author":"Neuzil","year":"2020"},{"key":"10.1016\/j.vaccine.2025.127515_bb0225","doi-asserted-by":"crossref","first-page":"e1483","DOI":"10.1016\/S2214-109X(21)00470-8","article-title":"Vi-TT\u2014a typhoid conjugate vaccine for infants and young children","volume":"9","author":"Wierzba","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2025.127515_bb0230","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.1016\/j.vaccine.2011.08.019","article-title":"Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity","volume":"29","author":"An","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127515_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126913","article-title":"Development of invasive non-typhoidal Salmonella conjugate vaccines and their evaluation in a trivalent formulation with typhoid conjugate vaccine","volume":"52","author":"An","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127515_bb0240","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1128\/IAI.03079-14","article-title":"Design of glycoconjugate vaccines against invasive African Salmonella enterica serovar typhimurium","volume":"83","author":"Rondini","year":"2015","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.127515_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100540","article-title":"Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: phase II, randomized, dose-scheduling, observer-blind study","volume":"27","author":"Capeding","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2025.127515_bb0250","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41541-022-00434-8","article-title":"Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose","volume":"7","author":"Capeding","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.127515_bb0255","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1473-3099(21)00455-2","article-title":"Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial","volume":"22","author":"Kumar Rai","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127515_bb0260","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3390\/vaccines8030540","article-title":"GMMA is a versatile platform to design effective multivalent combination vaccines","volume":"8","author":"Micoli","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127515_bb0265","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrmicro3525","article-title":"Outer-membrane vesicles from Gram-negative bacteria: biogenesis and function","volume":"13","author":"Schwechheimer","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2025.127515_bb0270","first-page":"1","article-title":"A multicenter, single-blind, randomized, phase-2\/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E\u2019s Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine (TyphiBEV\u2122) in healthy infant","author":"Thuluva","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127515_bb0275","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.vaccine.2010.11.022","article-title":"Vi-CRM197 as a new conjugate vaccine against Salmonella typhi","volume":"29","author":"Micoli","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127515_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025398","article-title":"Safety, immunogenicity and dose ranging of a new vi-CRM197 conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults","volume":"6","author":"van Damme","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2025.127515_bb0285","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1473-3099(13)70241-X","article-title":"Immunogenicity and safety of the vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and Southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials","volume":"14","author":"Bhutta","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127515_bb0290","doi-asserted-by":"crossref","first-page":"24443","DOI":"10.1073\/pnas.2005857117","article-title":"Short vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long vi-CRM197 conjugate vaccine","volume":"117","author":"Micoli","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2025.127515_bb0295","doi-asserted-by":"crossref","first-page":"2043103","DOI":"10.1080\/21645515.2022.2043103","volume":"18","author":"Thuluva","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127515_bb0300","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-072938","article-title":"Salmonella vaccine study in Oxford (SALVO) trial: protocol for an observer-participant blind randomised placebo-controlled trial of the iNTS-GMMA vaccine within a European cohort","volume":"13","author":"Hanumunthadu","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2025.127515_bb0305","first-page":"11","article-title":"Induction of broad immunity against invasive Salmonella disease by a quadrivalent combination Salmonella MAPS vaccine targeting Salmonella enterica serovars typhimurium, enteritidis, typhi, and Paratyphi A","author":"Boerth","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127515_bb0310","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/14760584.2023.2299384","article-title":"Multiple antigen presenting system (MAPS): state of the art and potential applications","volume":"23","author":"Malley","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127515_bb0315","doi-asserted-by":"crossref","first-page":"13564","DOI":"10.1073\/pnas.1307228110","article-title":"Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2025.127515_bb0320","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03790-21","article-title":"Carrier proteins facilitate the generation of Antipolysaccharide immunity via multiple mechanisms","volume":"13","author":"Zhang","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2025.127515_bb0325","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/vaccines11010091","article-title":"A bivalent MAPS vaccine induces protective antibody responses against Salmonella typhi and Paratyphi A","volume":"11","author":"Zhang","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2025.127515_bb0330","series-title":"Affinivax and Astellas present safety and immunogenicity data from phase 2 study of ASP3772, a novel 24 valent MAPS vaccine for Streptococcus pneumoniae","year":"2021"},{"key":"10.1016\/j.vaccine.2025.127515_bb0335","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00846-18","article-title":"A novel, multiple-antigen pneumococcal vaccine protects against lethal Streptococcus pneumoniae challenge","volume":"87","author":"Chan","year":"2019","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2025.127515_bb0340","unstructured":"Affinivax. MAPS platform: A next generation vaccine technology."},{"key":"10.1016\/j.vaccine.2025.127515_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2024.107828","article-title":"The effect of institutional case volume on post-operative outcomes after endarterectomy and stenting for symptomatic carotid stenosis","volume":"33","author":"Patel","year":"2024","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.vaccine.2025.127515_bb0350","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0140-6736(24)01494-6","article-title":"5-year vaccine protection following a single dose of vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial","volume":"404","author":"Qadri","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.127515_bb0355","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taae140","article-title":"Global burden, trends and inequalities for typhoid and paratyphoid fever among children younger than 15 years over the past 30 years","volume":"31","author":"Wang","year":"2024","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2025.127515_bb0360","doi-asserted-by":"crossref","DOI":"10.1017\/S0950268823000328","article-title":"Epidemiology of invasive meningococcal disease worldwide from 2010-2019: a literature review","volume":"151","author":"Pardo de Santayana","year":"2023","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2025.127515_bb0365","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1093\/ofid\/ofad020","article-title":"Nontyphoidal Salmonella invasive disease: challenges and solutions","volume":"10","author":"Crump","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127515_bb0370","first-page":"12","article-title":"Field experiences with handheld diagnostic devices to triage children under five presenting with severe febrile illness in a district hospital in DR Congo","author":"Tack","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.vaccine.2025.127515_bb0375","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.vaccine.2024.04.045","article-title":"Vaccine value profile for invasive non-typhoidal Salmonella disease","volume":"42","author":"Martin","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127515_bb0380","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41564-018-0295-3","article-title":"REASSURED diagnostics to inform disease control strategies, strengthen health systems and improve patient outcomes","volume":"4","author":"Land","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2025.127515_bb0385","doi-asserted-by":"crossref","first-page":"111","DOI":"10.12688\/wellcomeopenres.19012.2","article-title":"The challenge non-typhoidal Salmonella (CHANTS) consortium: development of a non-typhoidal Salmonella controlled human infection model: report from a consultation group workshop, 05 July 2022, London","volume":"8","author":"Smith","year":"2023","journal-title":"UK Wellcome Open Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25008126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25008126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T03:25:42Z","timestamp":1766546742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25008126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":77,"alternative-id":["S0264410X25008126"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127515","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-typhoidal Salmonella combination vaccines: clinical development plan and regulatory considerations","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127515"}}